Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department()

AIMS: Ibutilide is a rapid-acting antiarrhythmic drug with worldwide use for conversion of recent-onset atrial fibrillation. Vernakalant, approved in the EU in 2010, is likewise used intravenously, with proven efficacy and safety compared with placebo and amiodarone in randomized clinical trials. Th...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Europace
Hlavní autoři: Simon, Alexander, Niederdoeckl, Jan, Skyllouriotis, Ekaterini, Schuetz, Nikola, Herkner, Harald, Weiser, Christoph, Laggner, Anton N., Domanovits, Hans, Spiel, Alexander O.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2017
Témata:
Clinical Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5400093/
https://ncbi.nlm.nih.gov/pubmed/28175295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/europace/euw052
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky